Kamrab 150 Unit (Rabies Immunoglobulin (Human) SOLUTION) 150 UNIT

KAMRAB 150 Unit is a rabies immunoglobulin solution used for post-exposure prophylaxis. This product helps prevent rabies infection after potential exposure to the virus.

Strength

150 UNIT

Pack Size

2ML

Manufacturer / TM Owner

KAMADA LTD

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

KAMRAB 150 Unit is primarily used for post-exposure prophylaxis against rabies. It is administered intramuscularly to provide immediate protection when there is a risk of rabies infection. This solution is often used in conjunction with a rabies vaccine to enhance immunity. What is rabies immunoglobulin used for? It is used to neutralize the rabies virus and prevent the onset of the disease.

Side Effects

Common effects of KAMRAB 150 Unit may include localized reactions at the injection site, such as pain, swelling, or redness. Some individuals might experience mild systemic reactions like fever or headache. These effects are generally temporary and subside on their own.

Precautions & Warnings

KAMRAB 150 Unit should be handled with care and stored as per the manufacturer's instructions. It is essential to ensure that the solution is clear and free from particles before administration. Individuals with known allergies to rabbit proteins should consult a healthcare provider before use.

Avoid Interactions

KAMRAB 150 Unit may interact with other medications or substances. It is important to inform a healthcare provider about all current medications, including over-the-counter drugs and supplements, before administration. Alcohol and certain immunosuppressants might affect the efficacy of the solution.

References

Frequently Asked Questions

KAMRAB 150 Unit is used for post-exposure prophylaxis against rabies, helping to prevent infection after potential exposure to the virus.

KAMRAB 150 Unit is administered intramuscularly, typically at the site of exposure or as directed by a healthcare provider.

Common side effects may include localized reactions at the injection site, such as pain, swelling, or redness, and mild systemic reactions like fever or headache.

It is important to consult a healthcare provider before using KAMRAB 150 Unit with other medications, as interactions may occur.

Individuals with known allergies to rabbit proteins should consult a healthcare provider before using KAMRAB 150 Unit.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.